Table 3. Clinical efficacy (A) and adverse clinical outcomes (B) in patients with pulmonary embolism undergoing ultrasound-assisted catheter directed thrombolysis.
| (A) | |||
| Before UACDT | After UACDT | p value | |
| PASP (mmHg) | 60.77 ± 14.68 | 41.95 ± 14.07 | < 0.01 |
| PADP (mmHg) | 26.35 ± 8.42 | 17.51 ± 8.44 | < 0.01 |
| mean PA (mmHg) | 37.61 ± 9.57 | 25.7 ± 9.84 | < 0.01 |
| RV/LV ratio | 1.46 ± 0.50 | 0.79 ± 0.15 | < 0.01 |
| (B) | |||
| Overall (n = 42) | |||
| GUSTO bleeding | |||
| Moderate/severe | 18/9 | ||
| < 30-day mortality | 3 (7.14%) | ||
| > 30-day mortality | 3 (7.14%) | ||
| FU duration (m) | 18.69 ± 5.11 |
FU, follow-up; GUSTO, global utilization of streptokinase and tPA for occluded arteries; m, months; PADP, pulmonary arterial diastolic pressure; PASP, pulmonary arterial systolic pressure; UACDT, ultrasound-assisted catheter-directed thrombolysis therapy.